



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
67705/JPW/GJG/MMLSerial No.
~~10772,958~~ 10/12,958INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants: Eran Blaugrund et al.

Filing Date
November 13, 2003

Group 1617

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
✓	5 3 8 7 6 1 2	2/7/95	Youdim, et al.			
✓	5 4 5 3 4 4 6	9/26/95	Youdim, et al.;			
	5 4 5 7 1 3 3	10/10/95	Youdim, et al.;			
	5 6 6 8 1 8 1	9/16/97	Youdim, et al.;			
	5 5 7 6 3 5 3	11/19/96	Youdim, et al.;			
	5 5 3 2 4 1 5	7/2/96	Youdim, et al.;			
	5 5 9 9 9 9 1	2/4/97	Youdim, et al.;			
	5 7 8 6 3 9 0	7/28/98	Youdim, et al.;			
	5 5 1 9 0 6 1	5/21/96	Youdim, et al.;			
	5 8 9 1 9 2 3	4/6/99	Youdim, et al.;			
✓	5 7 4 4 5 0 0	4/28/98	Youdim, et al.;			
✓	6 3 1 6 5 0 4	2/7/95	Youdim, et al.;			
✓	20 04 00 10 0 3 8	1/15/04	Blaugrund et al.;			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No
WO 20 03 07 2 0 5 5	9/4/2003	PCT;			
WO 20 04 04 5 5 1 5	6/3/04	PCT;			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	Bensimon G, et al., (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. <u>N Engl J Med.</u> , 330(9):585-91;
	Bentué-Ferrer D, et al., (1996) Monoamine Oxidase B Inhibitors. <u>CNS Drugs.</u> , 6(3):217-36;
	Doble A. (1996) The pharmacology and mechanism of action riluzole. <u>Neurology</u> , 47 (Suppl. 1):S233-41;
	Eliash S, et al. (2001) "Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. <u>J. Neural Transm.</u> , 108:909-23;
	Ferrante RJ, et al., (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. <u>Ann. Neurol.</u> , 42:326-34;
	"Guidance for Industry: <i>In vivo</i> drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling." U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), November 1999;
✓	Gurney ME, et al., (1994) Motor neuron degeneration in mice that express a human superoxide dismutase mutation. <u>Science</u> , 264:1772-5;

EXAMINER

DATE CONSIDERED

12/21/06

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Eran Blaugrund et al.
Serial No.: 10/712,958
Filed: November 13, 2003
Exhibit A

[illegible]